Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya
PACTR202501835187008Phase 4Recruiting
- Sponsor
- Sabin Vaccine Institute
- Start
- Mar 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in cholera (3 arms), sponsored by Sabin Vaccine Institute. Primary endpoint: Vibriocidal geometric mean titer in plasma. Started Mar 2025; status: recruiting.
02
Conditions
cholera
Beyond the preview
Go deeper on PACTR202501835187008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202501835187008.